Oral bioavailability of BMS-986001 in healthy subjects (QBR113050)

• Research type

  Research Study

• Full title

  Study of the Absolute Oral Bioavailability of BMS-986001 in Healthy Subjects

• IRAS ID

  112818

• Contact name

  Philip Evans

• Sponsor organisation

  Bristol Myers-Squibb Research & Development

• Eudract number

  2012-002884-87

• Research summary

  The Sponsor is developing BMS-986001 (the study drug) for the potential treatment of HIV. The study will try to identify the oral bioavailability (how well the drug is absorbed into the bloodstream when taken by mouth) and pharmacokinetics (how the drug is taken up and broken down by the body), and the safety and tolerability of the study drug. In this study, healthy male subjects will receive a single oral dose of 400 mg of BMS-986001 (4 x 100 mg capsules) followed 2 hours later by a 100 æg intravenous (IV) dose of [14C]-BMS-986001.

• REC name

  HSC REC B

• REC reference

  12/NI/0135

• Date of REC Opinion

  4 Oct 2012

• REC opinion

  Further Information Favourable Opinion